Tid Tittel Kategori Vedlegg
10.02.2026
19:04
 Lytix Biopharma AS – Final result of Subsequent Offering and allocation of Offer Shares - -
10.02.2026
07:00
 Lytix Biopharma AS – Last day of the Subscription Period in the Subsequent Offering - -
05.02.2026
12:16
 Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report - -
27.01.2026
10:49
 Lytix Biopharma AS – Publication of Prospectus regarding Subsequent Offering and commencement of Subscription Period - -
26.01.2026
17:32
 Lytix Biopharma AS – EGM minutes - Subsequent Offering, ASA Conversion, Board Expansion and Board Authorization Approved -
1
14.01.2026
17:08
 Lytix Biopharma AS - New share capital registered - -
12.01.2026
11:52
 Lytix Biopharma AS – Notice of extraordinary general meeting 26 January 2026 -
1
09.01.2026
11:50
 Lytix Biopharma AS – Mandatory notification of trade by close associate of primary insider INSIDEHANDEL INS
1
09.01.2026
07:58
 Lytix Biopharma AS: Key information relating to potential subsequent offering - -
09.01.2026
07:49
 Lytix Biopharma AS: Private placement successfully completed with oversubscription INFORMASJON INF -
11.12.2025
13:39
 LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER INSIDEHANDEL INS
1
18.11.2025
07:00
 Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy RAPPORT RAP
2
14.11.2025
07:00
 Lytix Biopharma: Invitation to Q3 2025 Results Presentation -
1
11.11.2025
07:00
 Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital -
1
11.11.2025
07:00
 Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhospitalet -
1
10.11.2025
07:00
 New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide -
2
08.10.2025
07:00
 Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025 -
1